MLAB Mesa Laboratories, Inc.

NASDAQ
$127.14

Mesa Laboratories, Inc. (MLAB) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal In line Selling ran in line with MLAB's own trailing one-year pace, with 0% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 2 buyers in the last 90 days 4 sellers in the last 90 days
Insiders buying
4
5 transactions
Insiders selling
4
7 transactions
Purchases
$1.4M
14,109 shares
Sales
$1.6M
15,370 shares
Net activity
-$215.7K
purchases less sales

How much of that selling was preplanned? 0% planned / 100% discretionary

10b5-1 plan sales $0 0 transactions · 0 shares
Discretionary sales $1.6M 7 transactions · 15,370 shares

Largest single sale: $800.1K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: August 13, 2026 , by Tripeny R Tony .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Sullivan John James Director Sell 7,093 $112.80 $800.1K 17,834 −28.5% of holding
Kadia Siddhartha President and CEO Buy 7,093 $112.80 $800.1K 7,093
Tripeny R Tony Director Buy 900 $113.69 $102.3K 6,298
Sakys John CFO Sell 2,827 $89.50 $253.0K 19,785 −12.5% of holding
Archbold Brian David SVP Operations Sell 2,516 $89.50 $225.2K 6,377 −28.3% of holding
Crennen Lyndsey Elizabeth CAO Sell 442 $89.50 $39.6K 2,020 −18% of holding
Sakys John CFO Sell 1,223 $101.27 $123.8K 16,538 −6.9% of holding
Archbold Brian David SVP Operations Sell 1,151 $101.27 $116.6K 3,710 −23.7% of holding
Crennen Lyndsey Elizabeth CAO Sell 118 $101.27 $11.9K 1,473 −7.4% of holding
Ladiwala Shiraz Shabanali Director Buy 3,500 $72.23 $252.8K 8,523
Tripeny R Tony Director Buy 1,315 $76.00 $99.9K 5,398
Capone Mark Christopher Director Buy 1,301 $76.35 $99.3K 3,429

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.